Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia
share
Excerpt
- ChulaCov19 mRNA vaccine was found safe and immunogenic for primary immunization in clinical trials in Thailand.
- The Australian trial will evaluate the safety and immunogenicity of a booster dose of ChulaCov19 BNA159 mRNA vaccine in healthy volunteers.
- The collaborators of the trial are Chulalongkorn University, BioNet and Technovalia.
Article Summary
The phase 2 trial of the ChulaCov19 BNA159 mRNA vaccine as a booster dose in adults has been approved by the Human Research Ethics Committee (HREC) in Australia, according to a press release from Technovalia, Chulalongkorn University, and BioNet.
Following the disclosure of positive clinical safety and immunogenicity findings from earlier phase 1 and phase 2 studies of the ChulaCov19 mRNA vaccine, ethics approval is given to begin a phase 2 trial.
Professor Kiat Ruxrungtham and his team at the Chulalongkorn University Vaccine Research Center (ChulaVRC), Thailand, developed the ChulaCov19 mRNA vaccine in collaboration with Professor Drew Weissman of the University of Pennsylvania, USA. A phase 1 safety experiment was conducted in Thailand to assess the initial ChulaCov19 vaccine batch, which was produced in the United States. Then, after receiving two first doses of the vaccine, it was assessed in a comparative phase 2 safety and immunogenicity trial in Thai adults and senior volunteers. An mRNA vaccine authorised in Thailand was contrasted with the ChulaCov19 vaccine. In adults ages 18 to 64, the new multi-centre trial in Australia will evaluate the boosting immunity brought on by one dose of the Thailand-produced ChulaCov19 BNA159 vaccine.
BioNet has established an end-to-end manufacturing platform to produce mRNA vaccines from cell bank to encapsulation in record time. ChulaCov19 BNA159 mRNA vaccine is the fruit of a collaboration between Chulalongkorn University and BioNet. The mRNA technology platform enables the rapid development of new vaccines in 100 days from research to use in human trial. A second-generation mRNA vaccine against Omicron variant and the ancestral strain of SARS-CoV-2 virus is also in development.
Source: Bionet
Comments
Leave A Comment
Leave a Reply
